BeiGene (rebranded as BeOne Medicines in 2025) is a global oncology biopharmaceutical company founded in 2010, developing and commercializing cancer therapies worldwide. Its portfolio spans blood cancers and solid tumors, led by BRUKINSA (zanubrutinib), a BTK inhibitor, alongside programs in protein degradation (CDACs) and antibody-drug conjugates… - View it on GitHub